Cargando…

What to know about Omicron XBB.1.5

Detalles Bibliográficos
Autor principal:	Vogel, Lauren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2023
Materias:	News
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876584/ https://www.ncbi.nlm.nih.gov/pubmed/36690363 http://dx.doi.org/10.1503/cmaj.1096034

Ejemplares similares

XE, XD & XF: what to know about the Omicron hybrid variants
por: Basky, Greg, et al.
Publicado: (2022)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

XBB.1.5 emerges in the Americas: what it means to the region
por: Hotez, Peter
Publicado: (2023)

SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects – correspondence
por: Channabasappa, Nikhil K., et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection
por: Carr, Edward J, et al.
Publicado: (2023)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
por: He, Cai, et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

What’s important to know about the new COVID-19 variants?
por: Duong, Diana
Publicado: (2021)

XBB.1.5 an emerging threat: correspondence
por: Mohanty, Aroop, et al.
Publicado: (2023)

Possible threat of the Omicron subvariants XBB.1.5 and BF.7 to the Indian subcontinent: A correspondence
por: Ghosh, Shankhaneel, et al.
Publicado: (2023)

Long COVID-19 syndrome associated with Omicron XBB.1.5 infection: a case report
por: Espíndola, Otávio, et al.
Publicado: (2023)

An early look at Omicron
por: Vogel, Lauren
Publicado: (2022)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2
por: Popovic, Marko E.
Publicado: (2023)

Neutralizing response against SARS-CoV-2 Omicron BA.5 and XBB.1.5 in hemodialysis patients
por: Affeldt, Patrick, et al.
Publicado: (2023)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron
por: Amano, Masayuki, et al.
Publicado: (2023)

Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh
por: Habib, Mohammad Tanbir, et al.
Publicado: (2023)

Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants
por: Qu, Panke, et al.
Publicado: (2023)

Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants
por: Qu, Panke, et al.
Publicado: (2023)

Immunotherapy and fatigue: what we know and what we don’t know
por: Azeem Khan, Muhammad, et al.
Publicado: (2021)

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
por: Parums, Dinah V.
Publicado: (2023)

Serum Neutralization of Omicron XBB.1.5 in Kidney Transplant Recipients After Bivalent mRNA Booster Vaccination
por: Pedersen, Rune M., et al.
Publicado: (2023)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Another variant, XBB.1.5: will it be a tsunami for the Americas?
por: The Lancet Regional Health – Americas
Publicado: (2023)

… while many with omicron don't know they are infected
por: Wong, Carissa
Publicado: (2022)

Coding-complete genomes of XBB.1.16, XBB.2.3, FL.4 (alias of XBB.1.9.1.4), and XBB.3 of SARS-CoV-2 Omicron isolated from Bangladesh
por: Rahman, Saikt, et al.
Publicado: (2023)

Vaping and Health: What Do We Know about E-Cigarettes?
por: Arnold, Carrie
Publicado: (2014)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Re-emergence of SARS-CoV-2 Omicron subvariant XBB.1.5: present status, treatment, and future outlook – 2023
por: Akash, Shopnil, et al.
Publicado: (2023)

Alpha, Beta, Delta, Gamma: What’s important to know about SARS-CoV-2 variants of concern?
por: Duong, Diana
Publicado: (2021)

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023)

ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5
por: Yue, Can, et al.
Publicado: (2023)

Recent update on XBB.1.5 emerging novel mutation of COVID-19
por: Amin, Ruhul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i7j6i9lqpcpmvhg3238h8095jg